KLUS Pharma is Attending BIO Partnering at JPM

KLUS Pharma will attend BIO Partnering at JPM on Jan 11-15. Introduction and new updates are expected for several programs that are under development or co-development with our parent company Kelun-Biotech, including JAK inhibitor, HER2 ADC, HBV therapeutics, and anti-coagulants.

Potential partners with strong clinical and commercialization teams are welcome to connect during BIO Partnering at JPM.

We are also seeking partnerships for innovative projects in early discovery stages.